|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, November 03, 2008 ) New Delhi, India - According to our report “Global Vaccine Market Forecast to 2012”, addition of over 12 Million new cancer patients annually and unavailability of an effective treatment has created a strong interest among the pharmaceutical and biotech players in the cancer vaccine segment to come up with the most effective treatment in the shortest time possible. The report estimates that in 2007, the market for cancer vaccines, largely driven by the sales of cervical cancer vaccine Gardasil, reached US$ 2.2 Billion.
This report says that the cervical vaccine segment is expected to be the most lucrative in the cancer vaccine market. Cervical cancer vaccines Gardasil and Cervaix were among the top three bestselling vaccines in 2012. Apart from the cervical cancer segment - melanoma, lung lymphoma and prostate cancer vaccine segments are also seeing high activity with a number of products in late stage of development. However, to repeat the success of Gardasil in the market, each of these vaccines will have to establish its superiority as well as safety in terms of the currently established treatment protocols in order to first win the market approval and later on get reimbursement from health insurance agencies.
A number of new approvals will push the cancer vaccine segment to grow at a CAGR of over 30% between 2007 and 2012, enabling the cancer vaccine segment to occupy more than 26% of the overall global vaccine market in 2012, says the research report.
Apart from cervical vaccines, “Global Vaccine Market Forecast to 2012” also talks about vaccine segments like pneumococcal vaccines, polio vaccines, HIV vaccines, meningitis vaccines and Japanese encephalitis vaccines among others. This report contains market-based research and provides objective analysis on the global vaccine market. It gives a thorough statistical and analytical overview on the global vaccine market, and provides past, present and future data on the market structure and composition. The research extensively discusses the opportunities and challenges that are expected to arise within and from the vaccine market.
About RNCOS:
RNCOS, incorporated in the year 2002, is an industry research firm. It has a team of industry experts who analyze data collected from credible sources. They provide industry insights and analysis that helps corporations to take timely and accurate business decision in today's globally competitive environment.
For more information visit: http://www.rncos.com/Report/IM153.htm
Current Industry News: http://www.rncos.com/Blog/
RNCOS
Shushmul Maheshwari
91-11-4214-1229
publisher@rncos.com 
Source: EmailWire.com
|
|
|
|
